SCHEMBL4150336

SCHEMBL4150336

Cc1ccccc1NC(=O)c1c(NC(=O)c2cccs2)sc2c1CCCCC2

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.71
MAPT P10636 5/20 0.71
MEN1 O00255 4/20 0.71
LMNA P02545 4/20 0.71
KMT2A Q03164 4/20 0.71
ALDH1A1 P00352 4/20 0.71
NPC1 O15118 3/20 0.71
RAB9A P51151 2/20 0.71
GAA P10253 1/20 0.71
HPGD P15428 6/20 0.70
HSD17B10 Q99714 5/20 0.70
TP53 P04637 4/20 0.70
MAPK1 P28482 4/20 0.70
CASP1 P29466 3/20 0.70
CASP7 P55210 3/20 0.70
KDM4E B2RXH2 1/20 0.70
ESR1 P03372 1/20 0.70
ALOX15 P16050 1/20 0.70
TSHR P16473 1/20 0.70
HTT P42858 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21853900 0.85 ANO1 (0.76) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL20541666 0.84 ANO1 (0.76) SMN1; SMN2MAPTMEN1LMNAKMT2A
SCHEMBL12443131 0.83 TP53 (0.80) SMN1; SMN2MAPTMEN1LMNAKMT2A
SCHEMBL3918724 0.82 HPGD (1.00) SMN1; SMN2MAPTMEN1LMNAKMT2A
SCHEMBL3914843 0.81 HPGD (0.98) SMN1; SMN2MAPTMEN1LMNAKMT2A
SCHEMBL21853988 0.81 TP53 (0.79) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL20541774 0.81 ANO1 (1.00) SMN1; SMN2MAPTTP53ANO1ANO2
SCHEMBL20541725 0.81 TP53 (0.78) SMN1; SMN2MAPTLMNAALDH1A1TP53
SCHEMBL20541766 0.80 ANO1 (1.00) SMN1; SMN2MAPTTP53ANO1ANO2
SCHEMBL20541705 0.80 ANO1 (1.00) SMN1; SMN2MAPTTP53ANO1ANO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US claimed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP claimed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO claimed
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US disclosed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP disclosed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents TP53, BRDT, VHL SMN1; SMN2 155/4885MAPT 1629/4885MEN1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.